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Cell proliferationDuring embryogenesis the heart valves develop from undifferentiated mesenchymal endocardial cushions
(EC), and activated interstitial cells of adult diseased valves share characteristics of embryonic valve
progenitors. Twist1, a class II basic-helix–loop–helix (bHLH) transcription factor, is expressed during early
EC development and is down-regulated later during valve remodeling. The requirements for Twist1 down-
regulation in the remodeling valves and the consequences of prolonged Twist1 activity were examined in
transgenic mice with persistent expression of Twist1 in developing and mature valves. Persistent Twist1
expression in the remodeling valves leads to increased valve cell proliferation, increased expression of
Tbx20, and increased extracellular matrix (ECM) gene expression, characteristic of early valve progenitors.
Among the ECM genes predominant in the EC, Col2a1 was identiﬁed as a direct transcriptional target of
Twist1. Increased Twist1 expression also leads to dysregulation of ﬁbrillar collagen and periostin expression,
as well as enlarged hypercellular valve leaﬂets prior to birth. In human diseased aortic valves, increased
Twist1 expression and cell proliferation are observed adjacent to nodules of calciﬁcation. Overall, these data
implicate Twist1 as a critical regulator of valve development and suggest that Twist1 inﬂuences ECM
production and cell proliferation during disease.iovascular Biology, Cincinnati
ay, Cincinnati, OH 45229, USA.
utzey).
ry, University of Mississippi,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
In the United States, 20–30% of all congenital cardiovascular
malformations are associated with valve defects, and diseased valves
requiring replacement often have congenital anomalies (Loffredo,
2000; Roberts and Ko, 2005). Heart valve development is character-
ized by the transition of highly proliferative undifferentiated
progenitor cells of the endocardial cushions to quiescent valve
interstitial cells (VIC) embedded in a complex stratiﬁed extracellular
matrix (ECM) in the mature valves (Combs and Yutzey, 2009).
Likewise, the initial stages of valve disease are characterized by
activation of VICs, followed by increased production and disorgani-
zation of the valve ECM, leading to thickening of the valve leaﬂets
(Hinton et al., 2006; Rabkin et al., 2001; Rabkin-Aikawa et al., 2004).Embryonic valve progenitor cells are characterized by cell prolifera-
tion, migration, and primitive ECM production, which are also
characteristics of activated VICs in disease (Aikawa et al., 2006;
Rabkin-Aikawa et al., 2004; Schoen, 2008). Several signaling path-
ways and transcription factors, including the bHLH factor Twist1, have
been implicated in maintaining the valve progenitor phenotype
during development based on cell culture studies (Shelton and
Yutzey, 2008). However, the consequences of persistent expression of
early endocardial cushion transcription factors during later stages of
remodeling in vivo have not been previously demonstrated. More-
over, potential roles for regulators of valve progenitor cells in adult
human valve pathogenesis or repair have not been reported.
The development of the heart valves initiates with the formation of
endocardial cushions (EC) in the atrioventricular (AV) junction and
outﬂow tract (OFT) of the primitive heart tube (Combs and Yutzey,
2009). Heart valve progenitor cells arise from an epithelial to
mesenchymal transformation (EMT) and are a highly proliferative,
migratory, and undifferentiated mesenchymal cell population within
the EC. Heart valve remodeling during fetal and neonatal develop-
ment is characterized by the reduced proliferation of progenitor cells
with increased complexity and organization of stratiﬁed ECM in the
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2006). In addition, matrix metalloproteinases (MMPs) and ECM
protein genes, including collagens 2 and 9 are preferentially expressed
in EC, whereas ﬁbrillar collagens 1 and 3 are predominant in the
remodeling valves (Chakraborty et al., 2008). The mature AV and SL
valve leaﬂets are stratiﬁed into elastin, proteoglycan, and collagen-
rich ECM layers with VICs that exhibit little to no cell proliferation
(Combs and Yutzey, 2009). The molecular and cellular mechanisms
that govern the transition of proliferative, migratory, undifferentiated
valve progenitor cells of the EC into the differentiated, relatively
quiescent VICs of the mature valves are not well-characterized.
Twist1, a class II category basic-helix–loop–helix (bHLH) tran-
scription factor, regulates morphogenesis in a variety of developing
organ systems, including the heart, and also promotes EMT during
development and in tumor metastasis (Barnes and Firulli, 2009; Yang
et al., 2004). Twist1 haploinsufﬁciency in humans is associated with
Saethre–Chotzen syndrome, characterized by craniofacial abnormal-
ities, skeletal anomalies, and limb patterning defects (Reardon and
Winter, 1994). During development, Twist1 is highly expressed in EC,
and its expression is down-regulated during heart valve remodeling
(Chakraborty et al., 2008). In cultured avian embryonic EC, Twist1
promotes cell proliferation and migration, while inhibiting differen-
tiation (Shelton and Yutzey, 2008). However, the requirements for
Twist1 down-regulation in the remodeling valves and the conse-
quences of prolonged Twist1 activity in adult valves have not been
determined previously.
In this study, transgenic mice with persistent Twist1 expression in
remodeling and adult valves were generated in order to determine
the effects of prolonged Twist1 expression on valvulogenesis. Increased
Twist1 expression leads to increased cell proliferation, prolonged
expression of endocardial cushion ECM proteins, and abnormal valve
morphogenesis. In adult human diseased valves, Twist1 expression is
induced in regions of increased cell proliferation and ECM disorganiza-
tion. Together these studies provide in vivo evidence for Twist1 function
in heart valve development and disease.
Materials and methods
Generation of mice
Female CAG-CAT-Twist1 mice (Connerney et al., 2006) were bred
with Tie2Cremales (Kisanuki et al., 2001) (Jackson Laboratories, stock
number: 004128) to generate double transgenic embryos, neonates,
and adult offspring. Timed matings were established, with the
morning of an observed copulation plug set at E0.5. All studies were
performed on cohorts of CAG-CAT-Twist1;Tie2Cre double transgenic
(DTG) animals compared to CAG-CAT-Twist1 single transgenic (STG)
littermate controls. CAG-CAT-Twist1;Tie2Cre DTG animals were
obtained at expected Mendelian ratios, and no embryonic or adult
morbidity or mortality was observed. Genotyping for the Cre and
Twist1 transgenes was performed by PCR of DNA isolated from
embryonic yolk sacs or 3 weeks postnatal tail clips. The following
forward and reverse primer sequences were used: Cre: (5′-GCG GTC
TGG CAG TAA AAA CTA TC-3′ and 5′-GTG AAA CAG CAT TGC TGT CAC
TT-3′) and Twist1: (5′-GCA GTG GTG GAA TGC CTT TA-3′ and 5′-TGT
GGT ATG GCT GAT TAT GAT CTC-3′). All experiments involving animals
were carried outwith experimental protocols and procedures reviewed
and approved by the Cincinnati Children's Medical Center Biohazard
Safety Committee and Institutional Animal Care and Use Committee.
In situ hybridization (ISH) and immunohistochemistry
E12.5 whole embryos, E17.5, P7, and adult mouse hearts were
collected and washed in ice-cold 1× phosphate buffered saline (PBS)
and ﬁxed in 4% paraformaldehyde (PFA) overnight at 4 °C. Tissues
were subsequently processed for parafﬁn embedding as previouslydescribed (Lincoln et al., 2006) and sectioned at 14 μm for in situ
hybridization, 5 μm for histological Masson's trichrome staining, or
7 μm for immunoﬂuorescence. The generation of the Twist1 antisense
RNA probe and ISH were performed as previously described
(Chakraborty et al., 2008). For histology, following deparafﬁnization
and hydration through a graded ethanol series (100%, 95%, 75%, and
50%), tissues were stained with Masson's trichrome as previously
described (Hinton et al., 2006; Levay et al., 2008).
The following antibodies were used for immunoﬂuorescence (IF):
Myc (1:400; Cell Signaling, 2272), Phospho-Histone H3 (p-HH3)
(1:100; Millipore, 06-570), Ki-67 (1:50; Santa Cruz Biotechnology,
7846), Tbx20 (1:100; Orbigen, PAB 11248), Collagen (Col)2a1 (1:50;
Santa Cruz Biotechnology, 52657), Mmp2 (1:50; Abcam, 37150),
Mmp13 (1:50; Millipore, MAB 13426), Col1 (1:40; Millipore, AB
765P), Col3 (1:50; Rockland, 600-401-105-0.5), and Periostin (Postn)
(1:100; Abcam, 14041). Following deparafﬁnization and hydration,
tissue sections for IF were subjected to antigen retrieval in a
microwave oven with citrate buffer (10 mM citric acid, 0.05%
Tween-20, pH 6.0) for 4.5 min at 90% power, followed by 7 min at
80% power, and 7 min at 70% power and then 2 washes, separately in
distilled water and in 1×PBS for 2 min each. Tissue sections were
incubated with blocking reagent (1% BSA, 0.01% cold water ﬁsh skin
gelatin, 0.1% Tween-20 and 0.05% sodium-azide in 1×PBS) for 1 h at
room temperature, followed by overnight incubation at 4 °C with
primary antibodies with appropriate dilutions in 1×PBS using Cover-
well chamber slides (Grace Biolabs). Following incubations, sections
were washed in 1×PBS for 10 min, incubated with either
corresponding Alexa 488 or 568 ﬂuorescent-conjugated secondary
antibodies (Molecular Probes, 1:100) for 1 h, and washed in 1×PBS.
Nuclei were stained with ToPro3 (Molecular Probes, 1:1000) for
20 min at room temperature. Tissue sectionswere washed thoroughly
in 1×PBS for 10 min and mounted in Vectashield (Vectorlabs).
Fluorescent images were captured with Zeiss LSM 510 confocal
microscope and LSM version 3.2 SP2 software.
RNA isolation and real-time quantitative RT-PCR (qRT-PCR)
AV valves were isolated from E17.5 embryos or P7 neonates
generated frommatings of CAG-CAT-Twist1 females and Tie2Cremales.
After genotyping, valve tissue from 4 to 6 embryos or 2 to 3 neonates
was pooled for RNA isolation, and real-time qRT-PCR was performed
as previously described (Chakraborty et al., 2008). There was minimal
myocardial contamination of the valve RNA samples as indicated by
qRT-PCR analysis of the myocardial speciﬁc gene, cardiac troponin I
(cTnI). Forward and reverse primer sequences designed for qRT-PCR
are Tbx20: (5′-GCA GCA GAG AAC ACC ATC AA-3′ and 5′-AAT GAC ACG
CGG ATG GTG GGG AAC-3′), Col2a1: (5′-GGA AAG TCT GGG GAA AGA
GG-3′ and 5′-GGA ACC ACT CTC ACC CTT CA-3′), Mmp2: (5′-GAT GTC
GCC CCT AAA ACA GA-3′ and 5′-TGG TGT TCT GGT CAA GGT CA-3′),
Mmp13: (5′ ATC CTG GCC ACC TTC TTC TT-3′ and 5′-TTT CTC GGA GCC
TGT CAA CT-3′), Col3a1: (5′-GCA CAG CAG TCC AAC GTA GA-3′ and 5′-
TCT CCA AAT GGG ATC TCT GG-3′), Postn: (5′-CGA AGG GGA CAG TAT
CTC CA-3′ and 5′-AGG TCG GTG AAA GTG GTT TG-3′), and cTnI: (5′-
GAA GCA GGAGAT GGA ACG AG-3′ and 5′-TTA AAC TTG CCA CGG AGG
TC-3′). The primer sequences for Col1a1 qRT-PCR were described
previously (Chakraborty et al., 2008). All the ampliﬁcation reactions
were performed with 34 cycles of 94 °C for 30 s; 55 °C for 45 s; and
72 °C for 30 s. A standard curve was generated for each experimental
primer set with either E17.5 limb or E13.5 whole embryo cDNA, and
all values were normalized to ribosomal protein L7 expression
(Hemmerich et al., 1993). The average base-line levels of all the
genes relative to L7 expression in STG AV valves were calculated as
described previously (Sengupta et al., 2009). For each gene,
normalized expression in STG AV valves is set to 1 and then fold-
change is calculated for corresponding DTG AV valves. qRT-PCR
results represent three independent experiments (biological n=3)
169S. Chakraborty et al. / Developmental Biology 347 (2010) 167–179performed in triplicate (technical n=3). Statistical signiﬁcance of
observed differences was determined by Student's t-test (pb0.01).
Gene sequence homology analysis
A region containing a canonical Twist E-box (CANNTG) consensus
site within the intron I region of the mouse Col2a1 gene was iden-
tiﬁed through Ensembl alignment of the Col2a1 gene sequence
(ENSMUSG00000022483; Chromosome location 15: 97,805,402-
97,835,076). The conserved R1 locus in intron 1 of the Col2a1 gene
was identiﬁed by gene homology searches using rVISTA (Frazer et al.,
2004; Loots et al., 2002) and Genomatix with MatInspector (Quandt
et al., 1995) web-based analytical tools. Sequence alignments demon-
strate that the E-box consensus sequence within the murine Col2a1
intron 1 R1 (CACGTG) is conserved in rat and human Col2a1 genes.
Chromatin immunoprecipitation (ChIP)
Twist1 binding to chromosomal DNA in vivo was evaluated in mouse
E12.5 endocardial cushionsdissected from10 to12wild-type embryos for
each immunoprecipitation. Twist1 binding to DNA also was evaluated in
MC3T3-E1 (subclone 4) undifferentiated pre-osteoblasts cultured as
previously described,with 4×100 mmtissue culture plates at 90–95% cell
conﬂuency used for each immunoprecipitation (Chakraborty et al., 2008).
DNA/protein complexes were cross-linked for 10 min in formaldehyde
(Sigma) at a ﬁnal concentration of 1%. The ﬁxed cells were lysed and
sonicated twice for 5 s each with output 5 (Virsonic 60; Virtis) and a
2 minute refractory period. For immunoprecipitation, cell lysates were
incubated with an antibody against Twist1 (5 μg; Sigma) and incubated
overnight at 4 °C with gentle rocking. Immunoprecipitation with normal
rabbit IgG was used as a negative control. Chromatin immunoprecipita-
tions were performed according to the manufacturer's instructions
(EZChIP, Upstate), with the exception that protein A-agarose beads
were used. The immunoprecipitated and input DNA were subjected to
PCR using the following primers: Col2a1 (R1) 5′-ACC GAA GCC TGG AAA
GTG TA-3′ and 5′-TCC CCA CCT ACT GTC CAA AC-3′ ampliﬁes the murine
Col2a1 regulatory regioncontaining the canonical Twist1E-box (CACGTG)
binding site (R1). Primers used for the negative control region 2 (R2) are:
5′-ATA TTT AGA AAA TCT TGT TA-3′ and 5′-AGG GTA GTT GGT GAA ACT
AA-3′. PCR ampliﬁcation reactionswereperformedwith40 cycles of 94 °C
for 30 s; 55 °C for 1.5 min; and 72 °C for 3 min.
Plasmids, transfection and dual luciferase assay
The human Col2a1 (−577/3428) luciferase reporter construct
(Peng et al., 2008) was a generous gift from Dr. Mary Goldring,
Hospital for Special Surgery, Weill College of Medicine of Cornell
University, NY. Site-directed mutagenesis of the Region 1 (R1) E-box
was performed in the human Col2a1 luciferase reporter construct
using QuikChange Site-Directed Mutagenesis Kit (Stratagene) accord-
ing to manufacturer's instructions. The following primers were used
for mutagenesis: 5′-GGA TTT TTT TTT CTA CGT TTT TGG GCA CGT TTC
C-3′ and 5′-GGA AAC GTG CCC AAA AAC GTA GAA AAA AAA ATC C-3′.
Successful mutagenesis was veriﬁed by sequencing.
Transfections were performed in human embryonic kidney (HEK)
293 cells with FuGENE 6 transfection reagent (Roche) according to
manufacturer's protocols. In each experiment, 0.5 μg of either wild-
type or mutant luciferase reporter plasmid was cotransfected with
0.1 μg of either pcDNA-Twist1 (Firulli et al., 2007) (kind gift from Tony
Firulli, Indiana University School of Medicine) or empty
vector (pcDNA3.1). For all experiments, a Renilla luciferase reporter
pRL-TK (Promega) was cotransfected (0.01 μg) to normalize for
transfection efﬁciency. After 48 h, cells were washed (1×PBS) and
lysed using the passive lysis buffer (Promega), before measuring
ﬁreﬂy and Renilla luciferase activities using the Dual-Luciferase
Reporter Assay System (Promega). In each experiment, ﬁreﬂyluciferase activity was normalized to Renilla luciferase activity.
Normalized expression in pcDNA3.1 empty vector control was set to
1 and the fold increase was calculated in the corresponding
experimental sample. The average fold-change value was calculated
from six independent cotransfection experiments performed in
triplicate. Statistical signiﬁcance was determined by Student's t-test
(pb0.01).
Histology and immunohistochemistry on human valve tissues
Human aortic valve specimens were obtained from nonsyndromic
adult patients with calciﬁc aortic valve disease undergoing aortic
valve replacement (8 affected valves) and from age-matched patients
at the time of autopsy, who died of noncardiac causes (6 control
valves). Patients with a history of infective endocarditis, rheumatic
heart disease, or a genetic syndrome were excluded. Control valves
with evidence of calciﬁc nodules apparent by von Kossa staining were
excluded, however stippled mineralization was observed near the
hinge regions in 5/6 control aortic valves, consistent with aging. These
studies were approved by the Institutional Review Boards at
Cincinnati Children's Medical Center and the University of Cincinnati.
Tissues were processed and analyzed as previously described, and
sections (5 μm) were analyzed by Movat's pentachrome or von Kossa
histological staining (Hinton et al., 2006) or immunohistochemistry
(Snarr et al., 2007), essentially as described previously. The tissue
sections were prepared for staining by removal of parafﬁn wax in
xylenes, followed by rehydration through a graded ethanol series into
distilled water. For Tbx20, Twist1, and p-HH3 antibody staining, the
tissue was then subjected to antigen retrieval using a citric acid
antigen unmasking solution (Vector Labs, H-3300), according to
manufacturer's instructions, at high temperature and pressure in a
standard pressure cooker for 5 min (Snarr et al., 2007). For Col2
antibody staining, the sections were pretreated with 200 U/mL of
hyaluronidase (Sigma H3884) in 1×PBS (pH 5.45) at 37 °C for 3 h.
The valve tissue sections were incubated with primary antibodies
against Twist1 (1:40 dilution, mouse monoclonal; Santa Cruz, sc-
81417), p-HH3 (1:350 dilution, rabbit polyclonal; Upstate/Millipore,
06-570), Tbx20 (1:200 dilution, rabbit polyclonal; Orbigen 11248),
smooth muscle α-actin (SMA) (1:175 dilution, mouse monoclonal;
Sigma 0307), and Col2 (1:25, mouse monoclonal; Developmental
Studies Hybridoma Bank, University of Iowa II-II6B3). For colorimetric
immunohistochemistry, primary antibodies were detected using the
Ultra-sensitive ABC rabbit IgG staining kit (Tbx20, p-HH3) (Thermo
Scientiﬁc, 32054), or a peroxidase-conjugated goat anti-mouse
secondary antibody (SMA, Col2) (Jackson ImmunoResearch 115-
035-062). Antibody staining was visualized using the metal enhanced
DAB substrate staining kit (Thermo Scientiﬁc, 34065). The presence of
intact protein in control valve sections was conﬁrmed by robust
immunoreactivity with antibodies against SMA and Tbx20. For co-
immunoﬂuorescence, the Twist1 primary antibody was detected
using a horse anti-mouse biotinylated secondary antibody (from the
Vectastain Elite mouse IgG ABC staining kit; Vector Labs, PK-6102) in
combination with a streptavidin-conjugated Alexa ﬂuor 488 tertiary
antibody (Invitrogen, S11223). The p-HH3 immunoreactivity was
detected using an Alexa 568-conjugated goat anti-rabbit secondary
antibody (Invitrogen, A11011). Nuclei were stained with ToPro3
(Molecular Probes, 1:1000) in 1×PBS for 10 min at room temperature.
Fluorescence was visualized using a Zeiss LSM 510 confocal
microscope and LSM version 3.2 SP2 software.
Protein isolation and Western blotting
Protein lysates were isolated from E17.5 whole hearts using ice-cold
CelLytic MT tissue lysis buffer (Sigma), containing protease inhibitor
mixture (Pierce) and phosphatase inhibitor (Pierce) according to the
manufacturer's instructions. Western blots were performed as
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membranes were incubated with an alkaline phosphatase-conjugated
secondary antibody (1:4000; Thermo Scientiﬁc). Immunoblots were
developedusing chemiﬂuorescent detectionwith theVistra ECF reagent
(Amersham Biosciences) and scanned using a Storm 860 (Amersham
Biosciences). Signal intensities were quantiﬁed with ImageQuant 5.0
software (GE Healthcare). Twist1 (1:200; Sigma, T6451) and Myc
(1:200; Cell Signaling, 2272) primary antibodies were used for
immunoblot analyses. GAPDH (1:10,000; Santa Cruz Biotechnology,
25778) antibody reactivity was used as a loading control. Statistical
signiﬁcance was determined by Student's t-test (pb0.05).Valve morphometric analysis
Quantiﬁcation of mitral valve (MV) and aortic valve (AoV)
morphometry was performed on photomicrographs using ImageJ
software (NIH). For each time point (E17.5, P7, and 6.5 months),
measurements were made on images of 3 sequential tissue sections,
stained with Masson's trichrome or Movat's pentachrome, from 4
independent animals of each genotype. Mitral valve leaﬂet area was
measured for the region deﬁned by the distal junction with the
chordae tendineae to the insertion into the proximal ﬁbrousFig. 1. Ectopic Twist1 is expressed in late embryonic and postnatal AV valves in CAG-CAT-Tw
expression indicated by arrows in (A) E12.5 endocardial cushion (EC) cells, but not in E17.5
is apparent by immunoﬂuorescence (arrows, green nuclei) throughout the EC at E12.5 (C), in
CAT-Twist1 (STG) littermates show no immunoreactivity against the Myc antibody at E12.5
septum (IVS) is indicated. Similar results were obtained for n=4 individuals for each genocontinuity, that spans the interventricular septum. The collagen-rich
area of the ﬁbrous continuity was also measured independent of valve
leaﬂet area. Valve length was measured from the insertion of the
leaﬂet in the ﬁbrous continuity to the distal tip of the leaﬂet, excluding
the chordae tendineae. Valve thickness was measured at the distal,
middle, and proximal (hinge) aspects of the valve leaﬂets. The distal
thickness was measured at the widest aspect of the distal third or tip
of the valve, themiddle thicknesswasmeasured at the thinnest aspect
of the middle third of the valve, and the proximal (hinge) thickness
was measured at the widest aspect of the hinge of the valve. Aortic
valvemorphometric analyseswere performed as described previously
(Hinton et al., 2008). All the average measurements are reported with
standard error of mean (SEM) and were subjected to Student's t-test,
with pb0.05 considered signiﬁcant.Results
Tie2Cre-mediated Twist1 expression in embryonic and postnatal mouse
valves
During normalmouse heart development, Twist1mRNA is strongly
expressed in E12.5 EC (Fig. 1A), but little to no expression is detectedist1;Tie2Cre transgenic mice. In situ hybridization for mouse Twist1 reveals endogenous
(D) or P7 (G) mitral valve leaﬂets. Tie2Cre-mediated expression of Myc-tagged Twist1
E17.5 AV valves (F), and P7 MV leaﬂets (I) in CAG-CAT-Twist1;Tie2Cre (DTG) mice. CAG-
(B), E17.5 (E), or P7 (H). Cell nuclei are stained blue with ToPro3. The interventricular
type. Scale bar represents 100 μm for A–G and 50 μm for H and I.
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A conditional transgenic approach was used to achieve persistent
expression of Twist1 protein throughout the late stages of valve
development and in mature valves in mice. CAG-CAT-Twist1 trans-
genic mice express Myc-tagged Twist1 protein in the presence of Cre
recombinase (Connerney et al., 2006). These mice were bred with
Tie2Cre mice (Kisanuki et al., 2001) for expression of Twist1 in
endocardial cushion mesenchymal cells and their derivatives in the
remodeling and adult valves. For all experiments, single transgenic
CAG-CAT-Twist1 individuals (STG) were directly compared with CAG-
CAT-Twist1;Tie2Cre double transgenic (DTG) littermates. Induced
expression of transgenic Myc-tagged Twist1 protein is apparent in
E12.5 AV cushions (Fig. 1C), E17.5 AV valves (Fig. 1F) and in P7 mitral
valve (MV) leaﬂets (Fig. 1I) of DTG animals, compared to no
detectable expression in STG littermates (Figs. 1B, E and H).
Quantitation of the percent of cells with transgenic Myc-Twist1
expression in DTG animals reveals 49% expression in E12.5 EC, 65% in
E17.5 MV, and 39% in P7 MV. Overall, the DTG hearts have a 3.0 fold
increase in total Twist1 protein expression at E17.5, compared to
littermate STG hearts, as determined by Western blot (Fig. S1).
Therefore the CAG-CAT-Twist1;Tie2Cre DTG individuals exhibit persis-
tent Twist1 expression in late embryonic and postnatal heart valves,
compared to endogenous Twist1 levels.Persistent Twist1 expression leads to valve morphogenetic abnormalities
associated with increased cell proliferation and Tbx20 expression in
heart valves at E17.5
The effects of persistent Twist1 expression on mitral and aortic
valve leaﬂet morphogenesis were quantiﬁed (Table 1). Mitral and
aortic valve leaﬂet area, thickness, and length were measured at E17.5
and P7 for DTG animals with persistent Twist1 expression and STG
controls. For both MV and AoV leaﬂets, area, length, and thickness are
increased 2–3 fold in DTG versus STG animals at E17.5. Increased MV
and AoV leaﬂet area also is apparent in DTG animals at P7. HoweverTable 1
Morphometric analyses of mitral and aortic valve leaﬂets from E17.5 and P7 animals.
Mean values for at least n=3 individuals per group are indicated ±S.E.M. * indicates
statistical signiﬁcance as determined by Student's t-test pb0.05.






E17.5 Area mm2 (leaﬂet) 43.20±1.28 145.47±1.09*
Length 0.82±0.01 1.03±0.006*
Thickness at distal region 0.08±0.001 0.18±0.004*
Thickness at middle region 0.05±0.001 0.14±0.002*
Thickness at hinge region 0.07±0.002 0.27±0.009*
P7 Area (leaﬂet) 33.47±0.08 57.20±0.44*
Area (ﬁbrous continuity) 4.17±0.22 3.80±0.22
Length 0.83±0.002 1.02±0.005*
Thickness at distal region 0.03±0.001 0.03±0.002
Thickness at middle region 0.06±0.001 0.03±0.003
Thickness at hinge region 0.07±0.001 0.10±0.002






E17.5 Area mm2 (leaﬂet) 10.18±0.23 20.48±1.06*
Length 0.26±0.03 0.41±0.02*
Thickness at distal region 0.02±0.001 0.04±0.006
Thickness at middle region 0.03±0.002 0.08±0.006*
Thickness at hinge region 0.04±0.002 0.05±0.004
P7 Area (leaﬂet) 12.53±0.52 20.31±1.32*
Area (annulus) 4.68±0.34 13.02±0.35*
Length 0.31±0.01 0.32±0.02
Thickness at distal region 0.03±0.03 0.02±0.009
Thickness at middle region 0.01±0.01 0.02±0.006
Thickness at hinge region 0.02±0.02 0.03±0.012the morphogenetic defects are partially resolved after birth with no
signiﬁcant increase in thickness detected in the MV or AoV leaﬂets in
the DTG animals at P7. Together, these studies indicate that persistent
Twist1 expression in DTG animals leads to increased MV and AoV
leaﬂet area and thickness at E17.5, but that these morphogenetic
abnormalities are less apparent a week after birth.
During normal valve development in mice and humans, prolifer-
ation of interstitial cells decreases during remodeling and neonatal
stages (Aikawa et al., 2006; Hinton et al., 2006). In contrast, persistent
Twist1 expression in the CAG-CAT-Twist1;Tie2Cre DTG valves leads to
increased cell proliferation relative to STG controls, as detected by
immunoreactivity against p-HH3 (Figs. 2 and 3). MV leaﬂets from
E17.5 DTG embryos show an increased number of p-HH3 positive
nuclei (Fig. 2B), compared toMV leaﬂets from littermate STG embryos
(Fig. 2A). Quantitation of these results demonstrates that 23.1% of all
valve nuclei are p-HH3 positive in E17.5 DTG MV leaﬂets over-
expressing Twist1 compared to 8.3% of nuclei in littermate STG
controls (Fig. 2G). Essentially all of the cells with transgenic Twist1 are
proliferating, as indicated by co-localization of the cell proliferation
marker, Ki-67, and Myc-tagged Twist1 (Fig. 2D, yellow nuclei).
Likewise, increased cell proliferation also is detected in E17.5 DTG
AoV with persistent Twist1 expression (Figs. 3A–D). In the DTG AoV,
23.2% of the nuclei are p-HH3 positive compared to 7.0% in littermate
STG controls (Figs. 3C, D and G). However, persistent Twist1
expression does not result in increased cell proliferation in P7 DTG
MV or AoV leaﬂets compared to littermate STG controls (Figs. 2E and F
and 3E and F). There was no evidence of apoptosis in DTG or STG MV
at E17.5 or P7, as determined by TUNEL assay and cleaved caspase-3
immunostaining (Fig. S2). Together, these results demonstrate that
increased Twist1 expression promotes cell proliferation in E17.5
remodeling MV and AoV leaﬂets. However, increased Twist1
expression is not sufﬁcient to induce VIC proliferation after birth.
Tbx20, a T-box transcription factor, was previously identiﬁed as a
Twist1-responsive gene in chicken primary EC cells in culture
(Shelton and Yutzey, 2008). Therefore, expression of Tbx20 was
examined in DTG valves with persistent expression of Twist1. Tbx20
expression is increased in E17.5 DTG MV (Fig. 4B) and AoV (Fig. 5B)
compared to littermate STG controls (Figs. 4A and 5A). However,
Tbx20 expression is not signiﬁcantly changed in P7 DTG MV (Fig. 4E)
and AoV (Fig. 5D) leaﬂets, compared to littermate STG controls (Figs.
4D and 5C). Expression of Tbx20 mRNA was quantiﬁed by qRT-PCR,
demonstrating a 2-fold increase in expression of Tbx20mRNA in E17.5
DTG valves overexpressing Twist1 (Fig. 4C). However Tbx20 mRNA
levels are not signiﬁcantly changed in P7 DTG MV valves (Fig. 4F).
Together these data demonstrate that Tbx20 expression is responsive
to increased Twist1 expression in E17.5 DTG valves in vivo. However,
increased Twist1 expression in DTG valves does not alter Tbx20
expression at P7, consistent with the inability of Twist1 to affect cell
proliferation postnatally.
Expression of early ECM markers and matrix remodeling enzymes is
increased in valves with persistent expression of Twist1
During normal valve development, Collagen (Col)2a1 is highly
expressed in the immature ECM of the EC and is down-regulated
during valve remodeling later in embryogenesis (Chakraborty et al.,
2008). Similarly,Mmp2 andMmp13 are preferentially expressed in the
primitive EC and are responsive to Twist1 and Tbx20, respectively, in
avian EC cultures (Shelton and Yutzey, 2007, 2008). The persistent
expression of these ECmarker geneswas examined in E17.5 DTG valves
overexpressing Twist1. Persistent Twist1 expression resulted in in-
creased expressionof Col2a1 inMV(Fig. 6B) andAoV (Fig. 5F) compared
to littermate STG controls (Figs. 6A and 5E). In contrast, Twist1
overexpression does not apparently affect Col2a1 expression at P7 in
the AoV (Figs. 5G and H), consistent with results obtained for Tbx20
expression (Figs. 5C andD). In E17.5MV, increased expression ofMmp2
Fig. 3. Cell proliferation is increased in E17.5 CAG-CAT-Twist1;Tie2Cre (DTG) aortic
valves with persistent Twist1 expression. (A, B) Tie2Cre-mediated expression of Myc-
tagged Twist1 (green nuclei) in CAG-CAT-Twist1;Tie2Cre mice is detected throughout
the E17.5 aortic valve leaﬂets (arrows in B). In contrast, comparable heart sections from
littermate STG embryos show no immunoreactivity against the Myc epitope at E17.5
(arrows in A). (C, D) Persistent Twist1 expression in E17.5 aortic valves leads
to increased cell proliferation in CAG-CAT-Twist1;Tie2Cre DTG embryos, as indicated by
p-HH3 antibody reactivity (green nuclei indicated by arrows in D), compared to fewer
p-HH3 positive green nuclei in STG littermates (arrows in C). (G) p-HH3 reactivity was
quantiﬁed in 3 separate sections from 3 individuals of each genotype by cell counts of p-
HH3 positive nuclei/total nuclei. Increased p-HH3 positive nuclei (23.2%) were
observed in E17.5 DTG compared to 7.0% in STG valves. (E, F) In contrast, similar
levels of proliferation were detected in DTG and STG aortic valve leaﬂets at P7, as
indicated by percent p-HH3 positive nuclei in P7 DTG aortic valve leaﬂets (4.6%)
compared to littermate STG controls (4.2%). Cell nuclei are stained blue with ToPro3.
Statistical signiﬁcance is determined by Student's t-test, where * denotes pb0.01. Scale
bar represents 50 μm. Ao = aorta; AoV = aortic valve leaﬂets, and LV = left ventricle.
Fig. 2. Twist1 promotes increased cell proliferation in late embryonic but not in
postnatal AV valve leaﬂets. Increased cell proliferation as indicated by p-HH3
immunoﬂuorescence (green nuclei, arrowheads) is apparent in developing valves of
E17.5 DTG embryos (B) relative to STG littermates (A). The proliferation marker, Ki-67
(red) is colocalized with Myc-tagged (green) Twist1 protein in E17.5 DTG valve leaﬂets,
as indicated by yellow nuclei and arrowheads in D, compared to control STG leaﬂets
(arrowheads in C). Comparable p-HH3 immunoreactivity is observed in P7 DTG MV
leaﬂets (F) relative to the littermate STG controls (E). (G) p-HH3 reactivity was
quantiﬁed as the percent of total nuclei positive for pHH3 in 3 separate sections for 4
individuals of each genotype. The percent p-HH3 positive nuclei is increased in E17.5
DTG (23.1%) compared to STG (8.3%) valves. In contrast, similar levels of proliferation
are apparent at P7, as indicated by percent p-HH3 positive nuclei in P7 DTGmitral valve
leaﬂets (3.0%) compared to littermate STG controls (3.3%). Statistical signiﬁcance is
determined by Student's t-test, where * denotes pb0.01. Scale bar represents 50 μm.
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controls (Figs. 6C and E). At the transcriptional level, Col2a1 mRNA
expression is increased by 6.3-fold, Mmp2 by 3.5-fold, and Mmp13 by
2.6-fold in E17.5 DTG MV overexpressing Twist1 relative to littermateSTG controls (Fig. 6G). These data are consistent with Twist1 function
in maintaining an ECM characteristic of EC with increased production
of primitive ECMmarkers, including Col2a1 and Mmp13.
Fig. 4. Twist1 promotes Tbx20 expression in late embryonic AV valves. Tbx20 expression, as indicated by immunoﬂuorescence (green), is increased in E17.5 DTGMV leaﬂets (B, arrows)
compared to littermate STG controls (A, arrows). The left ventricle (LV) and interventricular septum (IVS) are indicated. (C) qRT-PCR analysis reveals a 2-fold up-regulation of Tbx20
mRNA in E17.5 DTG valves relative to littermate STG controls. Tbx20 expression is comparable in P7 DTG MV leaﬂets (E, arrows) and littermate STG controls (D, arrows) as detected by
immunoﬂuorescence and qRT-PCR (F). Normalized Tbx20 expression in E17.5 or P7 STG AV valves is set to 1 and then fold-change is calculated for corresponding DTG AV valves. The
average base-line levels of Tbx20 relative to L7 expression in STG AV valves are 1.14 at E17.5 and 2.03 in P7, respectively. The average fold increase is depicted, where n=3 and error bars
represent SEM. Statistical signiﬁcance is determined by Student's t-test, where * denotes pb0.05. Scale bar represents 50 μm (A, B) and 100 μm (D, E).
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morphogenesis
Expression of ﬁbrillar collagen, indicative of normal valve
remodeling, was examined in mice with persistent expression of
Twist1 in the developing valves. Expression of the matricellular
glycoprotein periostin (Postn), that promotes collagen ﬁbrillogenesis
in the developing valves and is regulated by Twist1, also was
examined (Connerney et al., 2006; Norris et al., 2008; Oshima et al.,
2002; Shelton and Yutzey, 2008). In the E17.5 DTGMVwith persistent
expression of Twist1, expression of Col1 (Fig. 7B) and Col3 (Fig. 7D) is
increased compared to littermate STG controls (Figs. 7A and C).
Expression of Postn also is increased in E17.5 DTG MV (Fig. 7F)
compared to littermate STG controls (Fig. 7E). Likewise, mRNA
expression of Col1a1 is increased by 2.2-fold, Col3a1 is increased by
3.3-fold, and Postn is increased by 2.7-fold in E17.5 DTGMV relative to
STG littermates (Fig. 7G). Since ﬁbrillar collagen is the major
structural component of the mature valves, the increased expression
of Col1, Col3 and Postn likely contributes to the increased valve
thickness and area observed in DTG MV at E17.5 (Table 1). In adults,
persistent Twist1 expression leads to less severe valve leaﬂet
abnormalities (Fig. S3 and Supplemental Table 1). However, increased
collagen deposition is observed in valve supporting structures and
could be an indicator of compromised valve function later in life.
Twist1 binds and activates a Col2a1 intronic regulatory region
Expression of Col2a1 is predominant at early stages of EC
development (Chakraborty et al., 2008) and also is signiﬁcantlyincreased in E17.5 AoV and MV with persistent expression of Twist1
(Figs. 5F and 6B). Therefore the ability of Twist1 to directly regulate
Col2a1 gene expression was examined. A region (R1) containing a
conserved canonical Twist E-box (CANNTG) consensus sequence was
identiﬁed in intron 1 of the Col2a1 gene (Fig. 8A). Importantly, the
mouse R1 E-box sequence (CACGTG) and surrounding nucleotides are
conserved in mouse, rat, and human Col2a1 intron I gene sequences
(Fig. 8B). Twist1 binding to the R1 region in vivo inmouse E12.5 EC and
in culturedMC3T3-E1pre-osteoblasts that express Twist1 (Chakraborty
et al., 2008) was assessed by chromatin immunoprecipitation (ChIP).
Cross-linked DNA/protein complexes were isolated directly from
dissected murine E12.5 EC or cultured MC3T3-E1 (subclone 4) pre-
osteoblasts. Immunoprecipitation with Twist1 antisera demonstrated
speciﬁc binding to R1 sequences in both E12.5 EC and MC3T3 cells
(Figs. 8C and D). Immunoprecipitation of R1 was not observed with the
IgG negative control. In addition no interaction with Twist1 was
observed for an adjacent region R2, which does not include an E-box
consensus sequence. Together, these data demonstrate speciﬁc binding
of Twist1 to the Col2a1 intronic R1 region in E12.5 EC in vivo and in
cultured MC3T3-E1 pre-osteoblast cells.
The ability of Twist1 to activate the Col2a1 intronic regulatory
element was examined in transfection assays performed in cultured
HEK 293 cells. A luciferase reporter construct (pGL2B-hCol2a1luc)
was obtained that includes human Col2a1 sequences (−577/+3428),
encompassing the promoter, exon 1, and intron 1 regulatory
sequences, including the conserved R1 E-box (CACGTG) (Peng et al.,
2008). Cotransfection of the wild-type (WT) Col2a1 plasmid with a
Twist1 expression plasmid results in an 8.8-fold trans-activation
relative to pcDNA empty vector control (Fig. 8E). Site-directed
Fig. 5. Twist1 promotes Tbx20 and Col2a1 expression in late embryonic but not in postnatal aortic valves. (A, B) Tbx20 expression as indicated by immunoﬂuorescence (green) is
increased in E17.5 DTG aortic valves (B, arrowheads) compared to littermate STG controls (A, arrowheads). Likewise, increased expression of Col2a1 is detected in E17.5 DTG aortic
valves (F, arrowheads) compared to littermate STG controls (E, arrowheads). Expression of Tbx20 (C, D arrowheads) and Col2a1 (G, H arrowheads) proteins is similar for STG and
DTG animals at P7. (E–H) Cell nuclei are stained blue with ToPro3. Scale bar represents 50 μm for A, B, E and F; and 100 μm for C, D, G and H. Ao= aorta; AoV= aortic valve, and LV=
left ventricle.
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Fig. 6. Expression of early ECM markers characteristic of endocardial cushions is
increased in CAG-CAT-Twist1;Tie2Cremouse valves at E17.5. Expression of ECM proteins
(A, B) Col2a1, (C, D) Mmp2 and (E, F) Mmp13 was detected by immunoﬂuorescence
(green, arrows) in E17.5 DTG mitral valves and littermate STG controls. (G) qRT-PCR
was used to determine mRNA expression levels of Col2a1, Mmp2 and Mmp13 (n=3).
The average level of expression for each gene in E17.5 STG AV valves is set to 1 and
the fold-changes are calculated for the E17.5 DTG AV valves. The average base-line
levels of expression relative to the L7 normalization gene are Col2a1 (3.13), Mmp2
(2.98), andMmp13 (0.30) in E17.5 STG AV valves. Statistical signiﬁcance is determined
by Student's t-test, where * denotes pb0.05. Scale bar represents 100 μm. IVS =
interventricular septum; LV = left ventricle.
Fig. 7. Heart valve ECM remodeling, as indicated by expression of ﬁbrillar collagens and
periostin, is abnormal in CAG-CAT-Twist1;Tie2Cre mice at E17.5. Expression of ECM
proteins (A, B) Col1, (C, D) Col3, and (E, F) Postn, was detected by immunoﬂuorescence
(green, arrows) in E17.5 DTG mitral valves and corresponding littermate STG controls.
(G) qRT-PCR demonstrates that Col1a1, Col3a1, and PostnmRNA levels are increased in
DTG versus STG (n=3) E17.5 embryos as described in Fig. 4. The average base-line
levels of Col1a1, Col3a1, and Postn are 1.04, 3.12, and 1.52 relative to L7 expression in
E17.5 AV valves, respectively. Statistical signiﬁcance is determined by Student's t-test,
where * denotes pb0.05. Scale bar represents 100 μm. IVS = interventricular septum;
LV = left ventricle.
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pGL2B-hCol2a1luc(WT) by changing the E-box consensus sequence
(CACGTG) to (TACGTT) in pGL2B-hCol2a1luc(Mut) (* in Fig. 8B). In
cotransfection assays, loss of the Twist1 binding site consensus inpGL2B-hCol2a1luc(Mut) essentially eliminates trans-activation by
Twist1 (Fig. 8E). Overall, these data demonstrate that the Col2a1 gene
includes a conserved E-box containing regulatory element bound
by Twist1 in E12.5 EC and trans-activated by Twist1 in an E-box
dependent manner in transfected cells.
Fig. 8. Twist1 binds directly and trans-activates a Col2a1 intronic regulatory region. (A) The mouse Col2a1 gene contains a conserved E-box sequence in region R1. Arrows indicate
PCR primer sequences for ampliﬁcation of R1 and of a negative control region 2 (R2), that does not contain an E-box consensus sequence. (B) The murine R1 E-box consensus
sequence (CACGTG) is conserved in rat and human Col2a1 genes. E-box consensus nucleotides mutated in R1 for transfection studies are indicated by *. (C–D) ChIP assays
demonstrate that Twist1 binds Col2a1 R1, but not R2 sequences, in mouse E12.5 EC (C) and MC3T3-E1 cells (D). (E) Cotransfection experiments performed in HEK293 cells
demonstrate that human Col2a1 (−577 to +3428) sequences linked to a pGL2-Basic reporter are trans-activated by Twist1 (8.8-fold). Mutagenesis of the conserved R1 E-box leads
to reduced trans-activation of Col2a1 regulatory sequences by Twist1. Trans-activation is represented as fold-change relative to the pcDNA empty vector control. Data are shown for a
representative experiment (from n=6) performed in triplicate. Statistical signiﬁcance is determined by Student's t-test, where * denotes pb0.01.
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areas of ECM disorganization and increased cell proliferation adjacent to
calciﬁed nodules
Given that Twist1 affects ECM protein production and promotes
proliferation of EC cells in culture and in vivo, we sought to determine
if Twist1 expression is induced during human valve pathogenesis.
Movat's pentachrome and von Kossa staining was performed on
human control and diseased aortic valve tissues in order to identify
the layers of stratiﬁcation (Figs. 9A and B) and areas of calciﬁcation
(Figs. 9C and D). In all control valves examined (n=6), three distinct
layers of ECM were apparent and no calciﬁed nodules were detected
(Figs. 9A and C). In contrast, extensive ECM disorganization (Fig. 9B)
and nodules of calciﬁcation, indicated by dark brown/black von Kossa
staining (* in Fig. 9D), are present in the diseased valves (n=8).
Twist1 protein expression was examined in diseased and control
human aortic valves. Immunoﬂuorescence reveals small clusters of
cells with increased expression of Twist1, with 5/8 diseased valves
analyzed having Twist1 positive immunostaining (Fig. 9F). The areas
of Twist1 expression are within regions of disorganized ECM and
adjacent to focal calciﬁcation nodules (* in Fig. 9F). Twist1 expression
is not detected in regions of the diseased valves that appear
unaffected, nor is Twist1 expression detected in 5/6 control valvesanalyzed (Fig. 9E). In human diseased aortic valves, Twist1 positive
nuclei that also express p-HH3 are detected by co-immunoﬂuores-
cence, indicating that some Twist1 positive cells are undergoing
mitosis (yellow nuclei, Fig. 9F). However, little to no cell proliferation
is apparent in the control valves (Fig. 9E). Likewise, increased Col2
protein expression is apparent in diseased aortic valves with
increased expression of Twist1 (Fig. 9H) compared to control
specimens (Fig. 9G). Together, these results demonstrate overlapping
regions of increased Twist1 expression, VIC proliferation, and Col2
protein expression in human aortic valve disease. Overall, these
ﬁndings are consistent with a mechanism whereby Twist1 activation
promotes cell proliferation and Col2 gene expression in aortic valve
pathogenesis.
Discussion
Here we demonstrate that Twist1 promotes progenitor cell
proliferation and affects expression of several ECM proteins, including
the target gene Col2a1, during heart valve development in mice.
Likewise, increased Twist1 expression is apparent in adult human
calciﬁc aortic valve disease. In mice, Tie2Cre-mediated expression of
Twist1 promotes cell proliferation and Tbx20 expression during late
embryonic heart valve development. Persistent Twist1 expression
Fig. 9. Twist1 and Collagen 2 expression is up-regulated and cell proliferation is increased in human aortic valve disease. (A, C, E, G) Human control aortic valve tissue collected at the
time of autopsy. (B, D, F, H) Human diseased aortic valve tissue obtained following valve replacement surgery. (A) Movat's pentachrome staining of normal human aortic valve tissue
delineates Fibrosa (F), Spongiosa (S), and Ventricularis (V) layers. (B) Pentachrome staining of the diseased human aortic valve demonstrates disorganized stratiﬁcation. The
presence of calciﬁcation in the diseased human valve is apparent by von Kossa staining (D, black staining indicated by white *), in comparison to the control tissue (C). Control and
diseased tissues were immunostained for Twist1 (E, F, green nuclei) and p-HH3 (E, F, red nuclei). Increased expression of Twist1 (F, green nuclei) and p-HH3 (F, red nuclei) is
observed in the diseased human aortic valve tissues adjacent to areas of calciﬁcation (indicated by *) and co-localization is demonstrated by yellow nuclei (F, white arrows). In
contrast, Twist1 and p-HH3 immunoreactivity is not apparent in control aortic valve tissue (E). Collagen 2 immunostaining (brown) also is increased in diseased aortic valves
(arrows in H) relative to controls (G). 5/8 diseased valves analyzed have Twist1 positive immunostaining, while 1/6 control valves have Twist1 positive immunostaining. Scale bar
represents 100 μm.
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including Col2a1, Mmp2 andMmp13 at this stage (E17.5). In E12.5 EC,
Twist1 binds to a conserved Twist1-responsive E-box element presentin the Col2a1 intron 1, supporting direct regulation of gene expression
by Twist1. Valve remodeling also is affected by increased Twist1
expression as indicated by thickening of AoV and MV leaﬂets in
178 S. Chakraborty et al. / Developmental Biology 347 (2010) 167–179addition to dysregulation of mature ﬁbrillar collagen deposition and
increased periostin expression at E17.5. In human diseased valves
with calciﬁcation, increased Twist1, Col2, and cell proliferation are
detected in overlapping regions. Co-immunoﬂuorescence provides
evidence that a subset of cells expressing Twist1 in the diseased valves
is actively proliferating. Overall, these data support a role for Twist1 as
a direct regulator of cell proliferation and ECM gene expression in
embryonic valve progenitor cells during development. In addition,
the detection of increased Twist1 expression in adult valve disease
provides initial evidence that Twist1 promotes cell proliferation and
Col2 expression during human valve pathogenesis.
A signiﬁcant reduction in cell proliferation is a feature of late
embryonic valve development, and normally little or no cell
proliferation is apparent in adult VICs (Aikawa et al., 2006; Hinton
et al., 2006; Lincoln et al., 2004). In chicken primary EC cells, Twist1 is
necessary and sufﬁcient to promote cell proliferation (Shelton and
Yutzey, 2008). In addition, Twist1 promotes Tbx20 expression in
avian primary EC explant cultures, and Tbx20 promotes expression of
the proto-oncogene N-myc in EC and cardiomyocytes (Cai et al., 2005;
Shelton and Yutzey, 2007, 2008). Consistent with these data, Tie2Cre-
mediated Twist1 overexpression is sufﬁcient to promote cell
proliferation and increased Tbx20 expression in E17.5 remodeling
valves. However, no signiﬁcant change is observed in either
proliferative indices or Tbx20 expression in postnatal valves over-
expressing Twist1. It is possible that Twist1 requires cooperating
factors that are absent in postnatal valves in order to promote cell
proliferation or that postnatal VICs are refractory to reentering the cell
cycle. Together, these ﬁndings demonstrate that persistent Twist1
expression is sufﬁcient to prolong the period of cell proliferation in
the E17.5 remodeling valve leaﬂets.
During normal valve development, the primitive, relatively
unstructured ECM of the EC remodels into highly organized and
stratiﬁed ECM of the mature valve leaﬂets. Valve leaﬂet remodeling is
characterized by the down-regulation of early ECM markers and
remodeling enzymes and increased expression of mature ECM
proteins, including ﬁbrillar collagens and elastin (Chakraborty et al.,
2008; Hinton et al., 2006). Persistent expression of Twist1 results in
increased expression of several early ECM markers, including Col2a1,
Mmp2, and Mmp13. A direct transcriptional regulatory mechanism is
supported by the identiﬁcation of intronic sequences of the Col2a1
gene that are bound by endogenous Twist1 in E12.5 EC in vivo and are
trans-activated by Twist1 in cultured cells. In addition, Twist1 and
Col2 protein expression are induced in overlapping regions of human
diseased aortic valves. Since Twist1 expression is normally down-
regulated during the stages when Col1a1 and Col3a1 expression is
induced, it is likely that ﬁbrillar collagen gene induction occurs by an
indirect mechanism (Chakraborty et al., 2008). Postn expression also
is increased with persistent expression of Twist1 in developingmouse
valves. In pre-osteoblast cells, Twist1 binds directly to a canonical E-
box sequence in the murine Postn promoter and trans-activates a
Postn reporter gene, supporting a direct regulatory mechanism
(Oshima et al., 2002). Additional candidate Twist1 downstream target
genes identiﬁed in mouse valves with persistent Twist1 expression
and in avian endocardial cushion cells include Tbx20, Mmp13, and
cadherin-11, but Twist1-responsive regulatory elements have not yet
been reported for these genes (Shelton and Yutzey, 2007, 2008).
Together, these data support Twist1 as a critical transcriptional
activator of multiple ECM and remodeling enzyme genes expressed in
the mesenchymal EC.
During valve pathogenesis, VICs are activated, apparent in increased
cell proliferation, ECM gene induction, and secretion of matrix
remodeling enzymes (Schoen, 2008). These properties of activated
VICs are shared with valve progenitors of the embryonic EC. The
detection of increased Twist1 expression and cell proliferation in human
aortic valve disease suggests that Twist1may inﬂuence cell proliferation
andVIC activation during disease. Increased Twist1 expression occurs insmall clusters of cells in regions displaying ECM disorganization, active
cell proliferation, and diseased calciﬁed nodules. Based on our studies in
mice, it is unlikely that increased expression of Twist1 alone is sufﬁcient
to cause calciﬁc aortic valve disease. However, the observed increase in
Twist1 expression in human diseased valves could contribute to cell
activation in response to injury, allowing for ECM reorganization
and increased cell proliferation. In addition, it is unclear whether
Twist1 reactivation during aortic valve disease is part of a protective
mechanism for valve repair, or if it has pathologic consequences leading
to valve calciﬁcation. The origins of activated VICs in valve disease have
not been identiﬁed, but they could arise from a resident stem cell
population or alternatively from extra-cardiac origins, such as mesen-
chymal or hematopoietic stem cells. There is increasing evidence that
regulatory programs active during valve development are reactivated in
disease and could be a mechanism for valve homeostasis or regener-
ation. Therefore, Twist1 function in valve progenitor cell proliferation
and ECM gene expression may hold future clinical relevance in human
valve disease diagnosis and therapies.
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